Evidence map›Paper›PMID 19955390›Full record

GuidelineSchizophrenia bulletin2010

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Robert W Buchanan, Julie Kreyenbuhl, Deanna L Kelly, Jason M Noel, Douglas L Boggs, Bernard A Fischer, Seth Himelhoch, Beverly Fang, Eunice Peterson, Patrick R Aquino and 2 more

Abstract readConsensus StatementPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Schizophrenia bulletin, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 344 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
344citing papers in PubMed, 16 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

344 citing papers in PubMed, 16 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Guideline
  10. Schizophrenia.Deutsches Arzteblatt international · 2020
    Pooled it
  11. Cannabis use and psychosis: a review of reviews.European archives of psychiatry and clinical neuroscience · 2020
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Trial
  18. Trial
  19. Trial
  20. Trial

284 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Robert W BuchananMaryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, PO Box 21247, Baltimore, MD 21228, USA. rwbuchanan@mprc.umaryland.edu
Julie Kreyenbuhl
Deanna L Kelly
Jason M Noel
Douglas L Boggs
Bernard A Fischer
Seth Himelhoch
Beverly Fang
Eunice Peterson
Patrick R Aquino
William Keller
Schizophrenia Patient Outcomes Research Team (PORT)

Funding

Schizophrenia PORT Treatment Recommendations Update 2008R13MH080593 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI KREYENBUHL, JULIE A. · 2007 to 2008
$164k
NIMH NIH HHS R13 MH080593
6 · The paper itself

Abstract

In light of the large number of studies published since the 2004 update of Schizophrenia Patient Outcomes Research Team psychopharmacological treatment recommendations, we conducted an extensive literature review to determine whether the current psychopharmacological treatment recommendations required revision and whether there was sufficient evidence to warrant new treatment recommendations for prespecified outcomes of interest. We reviewed over 400 articles, which resulted in 16 treatment recommendations: the revision of 11 previous treatment recommendations and 5 new treatment recommendations. Three previous treatment recommendations were eliminated. There were 13 interventions and/or outcomes for which there was insufficient evidence for a treatment recommendation, and a statement was written to summarize the current level of evidence and identify important gaps in our knowledge that need to be addressed. In general, there was considerable consensus among the Psychopharmacology Evidence Review Group and the expert consultants. Two major areas of contention concerned whether there was sufficient evidence to recommend specific dosage ranges for the acute and maintenance treatment of first-episode and multi-episode schizophrenia and to endorse the practice of switching antipsychotics for the treatment of antipsychotic-related weight gain. Finally, there continue to be major gaps in our knowledge, including limited information on (1) the use of adjunctive pharmacological agents for the treatment of persistent positive symptoms or other symptom domains of psychopathology, including anxiety, cognitive impairments, depressive symptoms, and persistent negative symptoms and (2) the treatment of co-occurring substance or medical disorders that occur frequently in individuals with schizophrenia.

Indexed as

Evidence-Based MedicineOutcome Assessment, Health CareSchizophrenic PsychologyAdvisory CommitteesAntipsychotic AgentsCombined Modality TherapyComorbidityDose-Response Relationship, DrugDrug Therapy, CombinationHumansPsychotropic DrugsRandomized Controlled Trials as TopicRecurrenceSchizophreniaAntipsychotic AgentsPsychotropic Drugs

Identifiers

PMID19955390
PMCPMC2800144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.